PMID- 25543014
OWN - NLM
STAT- MEDLINE
DCOM- 20151222
LR  - 20231213
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 76
IP  - 2-3
DP  - 2015 Mar
TI  - HLA-E polymorphism and clinical outcome after allogeneic hematopoietic stem cell 
      transplantation in Egyptian patients.
PG  - 161-5
LID - S0198-8859(14)00517-5 [pii]
LID - 10.1016/j.humimm.2014.12.017 [doi]
AB  - Human leukocyte antigen-E (HLA)-E in a non-classical major histocompatibility 
      complex (MHC) class I (Ib) molecule. HLA-E-peptide complex acts as a ligand for 
      natural killer (NK) cells and CD8+ T lymphocytes playing a dual role in natural 
      and acquired immune responses. The difference in expression levels between HLA-E 
      alleles was suggested to have impact on transplantation outcome. The aim of the 
      study is to evaluate the clinical effect of HLA-E alleles on transplantation in a 
      group of Egyptian patients. HLA-E genotyping was analyzed in eighty-eight 
      recipients of stem cell transplantation using polymerase chain 
      reaction-restriction fragment length polymorphism (PCR-RFLP). HLA-E*01:03 allele 
      showed a trend towards lower cumulative incidence of relapse at 2 years compared 
      to homozygous HLA-E*01:01 genotype (8% versus 21.5%, p=0.09, HR: 0.30, 95% CI: 
      0.91-1.69). HLA-E was the only factor showing near significant association with 
      relapse incidence. HLA-E polymorphism did not affect the cumulative incidence of 
      acute GVHD grades II-IV at 100 days, the 2-year cumulative incidence of extensive 
      chronic GVHD, transplant related mortality (TRM) or overall survival (OS). 
      CONCLUSION: the suggested association of HLA-E polymorphism with reduced risk of 
      relapse needs verification in a larger cohort. However, its proposed role in GVL 
      helps better understanding of alloreactivity of T cells and NK cells and their 
      implication in immunotherapy post allogeneic hematopoietic stem cell 
      transplantation.
CI  - Copyright (c) 2015 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Mossallam, Ghada I
AU  - Mossallam GI
AD  - Bone Marrow Transplantation Laboratory Unit, National Cancer Institute, Cairo 
      University, Cairo, Egypt. Electronic address: ghadamossallam@hotmail.com.
FAU - Fattah, Raafat Abdel
AU  - Fattah RA
AD  - Department of Medical Oncology, National Cancer Institute, Cairo University, 
      Cairo, Egypt.
FAU - El-Haddad, Alaa
AU  - El-Haddad A
AD  - Department of Pediatric Oncology, National Cancer Institute, Cairo University, 
      Cairo, Egypt.
FAU - Mahmoud, Hossam K
AU  - Mahmoud HK
AD  - Department of Medical Oncology, National Cancer Institute, Cairo University, 
      Cairo, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20141225
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Egypt
MH  - Female
MH  - Follow-Up Studies
MH  - Genotype
MH  - Graft Rejection/etiology/genetics/*immunology
MH  - Graft vs Host Disease/genetics/*immunology
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Humans
MH  - Killer Cells, Natural/*immunology
MH  - Leukemia, Myeloid/immunology/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic
MH  - Postoperative Complications/genetics/immunology
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Young Adult
MH  - HLA-E Antigens
OTO - NOTNLM
OT  - Graft versus leukemia (GVL)
OT  - HLA-E
OT  - Hematopoietic stem cell transplantation
OT  - Relapse
EDAT- 2014/12/30 06:00
MHDA- 2015/12/23 06:00
CRDT- 2014/12/28 06:00
PHST- 2014/06/20 00:00 [received]
PHST- 2014/10/20 00:00 [revised]
PHST- 2014/12/15 00:00 [accepted]
PHST- 2014/12/28 06:00 [entrez]
PHST- 2014/12/30 06:00 [pubmed]
PHST- 2015/12/23 06:00 [medline]
AID - S0198-8859(14)00517-5 [pii]
AID - 10.1016/j.humimm.2014.12.017 [doi]
PST - ppublish
SO  - Hum Immunol. 2015 Mar;76(2-3):161-5. doi: 10.1016/j.humimm.2014.12.017. Epub 2014 
      Dec 25.